Participants 45 84 3
children with autism spectrum disorders
Participants 242 302 5
children with autism spectrum disorders (ASD) ages 3-8 years
Participants 329 388 5
65 children with ASD who received one round of DMSA (3 days
Participants 391 490 4
Participants who had high urinary excretion of toxic metals were selected to continue on to phase 2
Participants 495 627 4
phase 2, 49 participants were randomly assigned in a double-blind design to receive an additional 6 rounds of either DMSA or placebo
